Pharmacokinetics, efficacy and safety of IMMUNATE® Solvent/Detergent (IMMUNATE® S/D) in previously treated patients with severe hemophilia A: Results of a prospective, multicenter, open-label phase III study

Acta Haematologica

Volumn 119, Issue 2, 2008, Pages 89-97

  Nemes, L ^a   Lissitchkov, T ^b   Dobaczewski, G ^c   Klukowska, A ^d   Komrska, V ^e   Zimmermann, R ^f   Auerswald, G ^g   Engl, W ^h   Abbuhl B ^h   Pavlova, B G ^h   Ehrlich, H J ^h  

^a NATIONAL MEDICAL CENTER   (Hungary)

^b National Center of Hematology and Transfusiology   (Bulgaria)

^c Pediatric Clinic of Hematology and Oncology   (Poland)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f Kurpfalz Hospital   (Germany)

^g Prof Hess Children's Clinic   (Germany)

^h BAXTER BIOSCIENCE   (Austria)

Author keywords

Factor VIII; Hemophilia A; IMMUNATE S D; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CLAVICLE FRACTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; FOREIGN BODY; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SACROILIITIS; TOOTH PAIN; TREATMENT RESPONSE;

ANTIBODIES; DRUG TOXICITY; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; PHARMACOKINETICS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 42949112991     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000118628     Document Type: Article

References (38)

1. DiMichele D: Immune tolerance therapy dose as an outcome predictor. Haemophilia 2003;9:382-386.
2. Federici AB, Mannucci PM: Advances in the genetics and treatment of von Willebrand disease. Curr Opin Pediatr 2002;14:23-33.
3. Brettler DB, Levine PH: Factor concentrates for treatment of haemophilia: which one to choose? Blood 1989;73:2067-2073.
4. Hoots WK: History of plasma-product safety. Transfus Med Rev 2001;15:3-10.
5. Eriksson B, Westman L, Jernberg M: Virus validation of plasma-derived products produced by Pharmacia, with particular reference to immunoglobulins. Blood Coagul Fibrinolysis 1994;5(suppl 3):37-44.
6. Barrett PN, Meyer H, Wachtel I, Eibl J, Dorner F: Determination of the inactivation kinetics of hepatitis A virus in human plasma products using a simple TCID50 assay. J Med Virol 1996;49:1-6.
7. Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, Hilgartner MW, Kernoff PB, Kunschak M, McMillan CW: Low risk of viral infection after administration of vapor-heated factor VIII concentrate. Transfusion 1992;32:134-138.
8. Mannucci PM: Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang 1993;64:197-203.
9. Shapiro A, Abe T, Aledort LM, Anderle K, Hilgartner MW, Kunschak M, Preston FE, Rivard GE, Schimpf K: Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group. Transfusion 1995;35:204-208.
10. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW: Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-831.
11. Turecek PL, Schonhofer W, Kreil TR: Immunate S/D A new Factor VIII von Willebrand complex concentrate; in Scharrer I, Schramm W (eds): 33rd Haemophilia Symposium Hamburg 2002. Berlin, Springer, 2004:117-134.
12. CPMP: Note for Guidance on the Clinical Investigation of Human Plasma Derived Factor VIII and IX Products; CPMP/BPWG/198/95 rev.1 .
13. Core Summary of Product Characteristics (SPC) for Human Plasma Derived and Recombinant Coagulation Factor VIII Products, CPMP/BPWG/1619/99.
14. Turecek PL, Gritsch H, Pichler L, Auer W, Fischer B, Mitterer A, Mundt W, Schlokat U, Dorner F, Brinkman HJ, van Mourik JA, Schwarz HP: In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997;90:3555-3567.
15. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I: A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII: C inhibitors in the haemophilia A population of Canada. Association of Haemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998;79:872-875.
16. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E: The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-251.
17. Auerswald G, Eberspächer B, Engl W, Güthner C, Koksch M, Kreuz W, Nimtz A, Pindur G, Scheel H, Schreiber JD, Siekmann J, Turecek PL, Wolf HH: Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate®). Semin Thromb Hemost 2002;28:203-213.
18. Ver Elst K, van Vliet H, Kappers-Klunne C, Leebeek F: In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Thromb Haemost 2004;92:67-74.
19. Nemes L, Lissitchkov T, Klukowska A, Dobaczewski G, Komrska V, Zimmermann R, Auerswald G, Engl W, Pavlova B, Abbühl B, Ehrlich HJ: Evaluation of PK, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A. Haemophilia 2007;13:9-11.
20. Wolf DM, Rokicka-Milewska R, Lopaciuk S, Skotnicki AB, Klukowska A, Laguna P, Windyga J, Kotitschke R, Struff WG: Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin® SDH in previously treated patients with severe haemophilia A. Haemophilia 2004;10:438-448.
21. Ahnström J, Berntorp E, Lindvall K, Sjörkman S: A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004;10:689-697.
22. Hay CRM: Propyhlaxis in adults with haemophilia. Haemophilia 2007;13:10-15.
23. Fischer K, Van Dijk K, Van Den Berg M: Results of prophylaxis started in adulthood. Haemophilia 2004;10:113-116 (22OC06).
24. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B: When should prophylactic treatment in patients with haemophilia A and B start? - The German experience. Haemophilia 1998;4:413-417.
25. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PL, Gringeri A, Ljung RC, Manco-Johnson MJ, Morfini M, Kilcoyne RF, Petrini P, Rodriguez-Merchan EC, Schramm W, Shapiro A, van den Berg HM, Hart C: Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(suppl 1):1-4.
26. Ghosh K, Shetty S, Mohanty D: Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay. Haemophilia 2001;7:9-12.
27. Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P: Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study. Haemophilia 2002;8:761-767.
28. Windyga J, Zarkova A, Walter O, Auerswald G: Clinical efficacy and safety of wilate, a novel, high purity VWF/FVIII concentrate with optimized pharmacokinetic properties in the treatment of von Willebrand disease. J Thromb Haemost 2005;3(suppl 1):P2062.
29. Rothschild C, Goudemand J, Alcalay M, Stieltjes N, Chambost H, Dirat G, Laubriat M, Duboullay C, Négrier C, Borel-Derlon A, Bridey F: Efficacy and safety of the first nanofiltered plasma-derived FVIII (FACTANE®) in previously treated haemophilia A patients. J Thromb Haemost 2003;1(suppl 1):P1619.
30. Dobrkovska A, Krzensk U, Chediak JR: Pharmakokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia 1998;4:33-39.
31. Powell JS, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson AR, Hurst D: Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A. Haemophilia 2000;6:140-149.
32. Scharrer I, Ehrlich HJ: Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001;7:346-348.
33. Addiego JE Jr, Gomperts E, Liu SL, Bailey P, Courter SG, Lee ML, Neslund GG, Kingdon HS, Griffith MJ: Treatment of haemophilia with a highly purified factor VIII concentrate prepared by immunoaffinity chromatography. Thromb Haemost 1992;67:19-27.
34. Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM: Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004;10:428-437.
35. White GC 2nd, Courter S, Bray GL, Lee M, Gomperts ED: A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. Thrombosis and Haemostasis 1997;77:660-667.
36. Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E: Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. International Kogenate FS Study Group. Thromb Haemost 2000;83:811-816.
37. Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G Gitel S, Inbal A: Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P ™) in patients with von Willebrand disease. Thromb Haemost 1999;81:229-233.
38. Thompson AR, Gill JC, Ewenstein BM, Mueller-Veltens G, Schwartz BA: Successful treatment of patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®). Haemophilia 2004;10:42-51.